Advertisement
BELLUS Health Inc. (BLU)
NASDAQ: BLU
· Real-Time Price · USD
14.74
0.00 (0.00%)
At close: Jun 28, 2023, 7:59 PM
0.00% (1D)
| Bid | 14.73 |
| Market Cap | 1.87B |
| Revenue (ttm) | 3.17B |
| Net Income (ttm) | -108.19M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -20.198630136986303 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 14.75 |
| Volume | 2,839,350 |
| Avg. Volume (20D) | 5,381,551 |
| Open | 14.74 |
| Previous Close | 14.74 |
| Day's Range | 14.74 - 14.75 |
| 52-Week Range | 6.38 - 14.76 |
| Beta | -0.28 |
About BLU
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada....
Industry Biotechnology
Sector Healthcare
IPO Date Oct 27, 2000
Employees 74
Stock Exchange NASDAQ
Ticker Symbol BLU
Website https://www.bellushealth.com